Takeda Oncology
David A. is an accomplished leader in global medical affairs and business development within the oncology sector, currently serving as Head of Pipeline, BD & Hematology at Takeda Oncology since March 2021. With a strong background in cross-functional leadership, David has managed multiple myeloma and oncology portfolios, overseeing clinical and pre-clinical assets while also directing strategic initiatives and training programs. Prior experience includes roles at AbbVie and Pharmacyclics, where David led brand strategy and external collaborations. With a foundational background in research and a Doctorate in Biology from UC San Diego, as well as an MBA from Duke University, David has effectively combined scientific expertise with business acumen throughout a diverse career spanning several prestigious organizations.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.